Perrigo enjoys sales increase for FY 2007
ALLEGAN, Mich. New store brand smoking cessation product introductions helped boost the Consumer Healthcare segment of Perrigo, a private label manufacturer. Consumer sales for fiscal year 2007, ended June 20, totaled $1 billion, an increase of 4 percent.
“It was another strong new product year with $77 million in new product sales [$69 million in the consumer health segment], led by smoking cessation,” reported Perrigo president anad chief executive officer Joe Papa. “On top of that, we also introduced $59 million of newly reformulated products to the market.”
B&L, Alcon settle lawsuit over color scheme
ROCHESTER, N.Y. Bausch & Lomb and Alcon Laboratories earlier this week settled the lawsuit recently filed by B&L concerning Alcon’s promotional claims about Bausch & Lomb’s ReNu MultiPlus multi-purpose disinfecting solution.
The suit centered on Alcon’s use of a color-coded chart showing differences in superficial punctate transient corneal staining profiles observed in Dr. Gary Andrasko’s research. To address Bausch & Lomb’s concern over the red-yellow color scheme of Dr. Andrasko’s corneal staining grid, Alcon has agreed to change the red-yellow color scheme used in its promotional materials.
The use of the color scheme in Alcon’s materials was not intended to communicate that the lens-solution combinations designated red or yellow meant danger or caution, and was not meant to suggest an increased risk of corneal infection.
In light of Alcon’s and B&L’s agreements, the lawsuit has been dismissed with prejudice, without any payment of damages from either party.
Adams ranks high on Deloitte list
Adams Respiratory Therapeutics ranked No. 7 in Deloitte & Touche’s Technology Fast 50 Program for New Jersey, a ranking of the 50 fastest growing technology, media, telecommunications and life sciences companies in the area, the company announced Monday.
“We are very proud to be recognized by Deloitte for achieving a revenue growth rate of 1,638 percent from 2002 to 2006,” commented Michael Valentino, chief executive officer of Adams, on the distinction. “It has been exhilarating to see the things we’ve done take hold. Our unique regulatory strategy for Mucinex coupled with our synergistic blend of consumer and professional marketing for the Mucinex brand helped fuel our phenomenal growth over the past five years. … We now market nine over-the-counter products with multiple new product introductions planned this fall. Additionally, we also plan to expand into the prescription respiratory market as early as 2008.”